This is a renewal application for support of the Yale University Digestive Disease Research Core Center, a multi-disciplinary Center whose research focus is Liver Structure, Function and Disease. Thirty-five independently funded investigators comprise a research based of approximately $8.5 million. Current research programs in the Center are distributed in 10 departments of the University including Biology, Cell Biology, Cellular and Molecular Physiology, Epidemiology and Public Health, Human Genetics, Medicine, Pathology, Pediatrics, Pharmacology and Surgery. The research based focuses on six major areas: 1) Cellular and Molecular Biology of the Liver, 2) Hepatic Transport Mechanisms, 3) Basic Biology of Disease Processes, 4) Studies of the Hepatic and Splanchnic Circulation, 5) Clinical Hepatology, and 5) Liver Immunology. The research programs in the Center are quite broad and range from fundamental studies of the biology of liver research programs in the Center are quite broad and range from fundamental studies of the biology of liver cells to clinical therapeutic trials of immediate clinical relevance to the diagnosis and treatment of chronic liver cells to clinical therapeutic trials of immediate clinical relevance to the diagnostic and treatment of chronic liver cells to clinical therapeutic trials of immediate clinical relevance to the diagnosis and treatment of chronic liver cells to clinical therapeutic trials of immediately clinical relevance to the diagnosis and treatment of chronic liver disease in patients with these disorders. The major goals of the Center continue to be: 1) to stimulate multi-disciplinary interactions between basic and clinical faculty and departments, 2) to provide in-depth training environment, 3) to efficiently organize time consuming, often costly techniques and procedures in core facilities for use by multiple investigators, 4) to stimulate basic scientists to direct their talents and technologies to specific areas of research interest in the Center, 5) to promote important new research and training opportunities through a pilot feasibility project program, and 6) to create an intellectual environment within opportunities through a pilot feasibility project program, and 6) to create an intellectual environment within the institution in the field of Hepatology and to foster collaborations both within and outside the institution. To achieve these goals the Center is organized into five Core Facilities including both within and outside the institution. To achieve these goals the Center is organized into five Core Facilities including: 1) Administrative Core, 2) Cell Isolation, Culture and Organ Perfusion Core, 3) Molecular Biology Core, and 4) Imaging Core. A Pilot Feasibility Program supports small 1-2 year grants for new scientific initiatives. An Enrichment program consists of a seminar program, journal clubs, symposia, retreats and Center newsletters.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK034989-20
Application #
6619441
Study Section
Special Emphasis Panel (ZDK1-GRB-4 (J2))
Program Officer
Podskalny, Judith M,
Project Start
1984-09-30
Project End
2004-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
20
Fiscal Year
2003
Total Cost
$1,000,000
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Pan, Qiong; Zhang, Xiaoxun; Zhang, Liangjun et al. (2018) Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. Gastroenterology 155:1578-1592.e16
Jakab, Sofia Simona; Garcia-Tsao, Guadalupe (2018) Screening and Surveillance of Varices in Patients With Cirrhosis. Clin Gastroenterol Hepatol :
Fiorotto, Romina; Amenduni, Mariangela; Mariotti, Valeria et al. (2018) Src kinase inhibition reduces inflammatory and cytoskeletal changes in ?F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology 67:972-988
Sari, Sinan; Dalgic, Buket; Muehlenbachs, Atis et al. (2018) Prototheca zopfii Colitis in Inherited CARD9 Deficiency. J Infect Dis 218:485-489
Yu, Dongke; Cai, Shi-Ying; Mennone, Albert et al. (2018) Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int 38:1128-1138
Garcia-Tsao, Guadalupe (2018) Regression of HCV cirrhosis: Time will tell. Hepatology 67:1651-1653
Hung, Adelina; Garcia-Tsao, Guadalupe (2018) Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. Liver Int 38:1437-1441
Kaffe, Eleanna; Fiorotto, Romina; Pellegrino, Francesca et al. (2018) ?-Catenin and interleukin-1?-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis. Hepatology 67:1903-1919
Goldberg, David S; Levy, Cynthia; Yimam, Kidist et al. (2018) Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clin Gastroenterol Hepatol 16:591-593
Cadamuro, Massimiliano; Stecca, Tommaso; Brivio, Simone et al. (2018) The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864:1435-1443

Showing the most recent 10 out of 763 publications